Copy to clipboard 
Onkos Surgical introduced the JTS Extendible Prosthesis, a novel growing implant designed for pediatric patients with bone cancer, and unveiled its new manufacturing and R&D innovation center at its Parsippany, NJ headquarters to support the integration and growth of the technology.
The JTS Extendible Prosthesis, acquired from Stryker last year, is a growing implant with a significant body of clinical evidence for pediatric patients with bone cancer. With the use of magnetic technology, the implant expands non-invasively to accommodate the patient’s natural growth curve, preserving lower limb length equality for young patients with bone loss due to cancer. The addition of the JTS technology expands the company’s access and ability to provide solutions for pediatric patients.
Patrick Treacy, Onkos Founder and CEO, said, “This is a transformative time for our company, which was founded on serving this group of surgeons treating complex orthopaedic procedures and the patients they care for. Pediatric sarcoma patients, who are candidates for the JTS growing prosthesis, often have complex treatment cycles in which we need to deliver precision designs in a very specific treatment window. Our investment in manufacturing innovation and design expertise will make a big difference in the future for these surgeons, patients, and families and we couldn’t be more proud to serve their needs.”
“This milestone reflects an exciting evolution for Onkos as the company accelerates our investments to serve the pediatric musculoskeletal oncology space and broaden our Precision Orthopaedics portfolio. The new manufacturing facility and innovation center will enable a more agile production environment and provide a world-class experience for our customers. Everything about the design of the facility is geared toward increasing speed, capacity and ownership of the supply chain to optimize our ability to deliver personalized devices,” said Gary Thomas, Onkos VP of Manufacturing.
Source: Onkos Surgical
Onkos Surgical introduced the JTS Extendible Prosthesis, a novel growing implant designed for pediatric patients with bone cancer, and unveiled its new manufacturing and R&D innovation center at its Parsippany, NJ headquarters to support the integration and growth of the technology.
The JTS Extendible Prosthesis, acquired from Stryker...
Onkos Surgical introduced the JTS Extendible Prosthesis, a novel growing implant designed for pediatric patients with bone cancer, and unveiled its new manufacturing and R&D innovation center at its Parsippany, NJ headquarters to support the integration and growth of the technology.
The JTS Extendible Prosthesis, acquired from Stryker last year, is a growing implant with a significant body of clinical evidence for pediatric patients with bone cancer. With the use of magnetic technology, the implant expands non-invasively to accommodate the patient’s natural growth curve, preserving lower limb length equality for young patients with bone loss due to cancer. The addition of the JTS technology expands the company’s access and ability to provide solutions for pediatric patients.
Patrick Treacy, Onkos Founder and CEO, said, “This is a transformative time for our company, which was founded on serving this group of surgeons treating complex orthopaedic procedures and the patients they care for. Pediatric sarcoma patients, who are candidates for the JTS growing prosthesis, often have complex treatment cycles in which we need to deliver precision designs in a very specific treatment window. Our investment in manufacturing innovation and design expertise will make a big difference in the future for these surgeons, patients, and families and we couldn’t be more proud to serve their needs.”
“This milestone reflects an exciting evolution for Onkos as the company accelerates our investments to serve the pediatric musculoskeletal oncology space and broaden our Precision Orthopaedics portfolio. The new manufacturing facility and innovation center will enable a more agile production environment and provide a world-class experience for our customers. Everything about the design of the facility is geared toward increasing speed, capacity and ownership of the supply chain to optimize our ability to deliver personalized devices,” said Gary Thomas, Onkos VP of Manufacturing.
Source: Onkos Surgical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
